Cargando…
The crystal structure of alanine racemase from Streptococcus pneumoniae, a target for structure-based drug design
BACKGROUND: Streptococcus pneumoniae is a globally important pathogen. The Gram-positive diplococcus is a leading cause of pneumonia, otitis media, bacteremia, and meningitis, and antibiotic resistant strains have become increasingly common over recent years. Alanine racemase is a ubiquitous enzyme...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3146814/ https://www.ncbi.nlm.nih.gov/pubmed/21612658 http://dx.doi.org/10.1186/1471-2180-11-116 |
_version_ | 1782209240635539456 |
---|---|
author | Im, Hookang Sharpe, Miriam L Strych, Ulrich Davlieva, Milya Krause, Kurt L |
author_facet | Im, Hookang Sharpe, Miriam L Strych, Ulrich Davlieva, Milya Krause, Kurt L |
author_sort | Im, Hookang |
collection | PubMed |
description | BACKGROUND: Streptococcus pneumoniae is a globally important pathogen. The Gram-positive diplococcus is a leading cause of pneumonia, otitis media, bacteremia, and meningitis, and antibiotic resistant strains have become increasingly common over recent years. Alanine racemase is a ubiquitous enzyme among bacteria and provides the essential cell wall precursor, D-alanine. Since it is absent in humans, this enzyme is an attractive target for the development of drugs against S. pneumoniae and other bacterial pathogens. RESULTS: Here we report the crystal structure of alanine racemase from S. pneumoniae (Alr(SP)). Crystals diffracted to a resolution of 2.0 Å and belong to the space group P3(1)21 with the unit cell parameters a = b = 119.97 Å, c = 118.10 Å, α = β = 90° and γ = 120°. Structural comparisons show that Alr(SP )shares both an overall fold and key active site residues with other bacterial alanine racemases. The active site cavity is similar to other Gram positive alanine racemases, featuring a restricted but conserved entryway. CONCLUSIONS: We have solved the structure of Alr(SP), an essential step towards the development of an accurate pharmacophore model of the enzyme, and an important contribution towards our on-going alanine racemase structure-based drug design project. We have identified three regions on the enzyme that could be targeted for inhibitor design, the active site, the dimer interface, and the active site entryway. |
format | Online Article Text |
id | pubmed-3146814 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-31468142011-07-31 The crystal structure of alanine racemase from Streptococcus pneumoniae, a target for structure-based drug design Im, Hookang Sharpe, Miriam L Strych, Ulrich Davlieva, Milya Krause, Kurt L BMC Microbiol Research Article BACKGROUND: Streptococcus pneumoniae is a globally important pathogen. The Gram-positive diplococcus is a leading cause of pneumonia, otitis media, bacteremia, and meningitis, and antibiotic resistant strains have become increasingly common over recent years. Alanine racemase is a ubiquitous enzyme among bacteria and provides the essential cell wall precursor, D-alanine. Since it is absent in humans, this enzyme is an attractive target for the development of drugs against S. pneumoniae and other bacterial pathogens. RESULTS: Here we report the crystal structure of alanine racemase from S. pneumoniae (Alr(SP)). Crystals diffracted to a resolution of 2.0 Å and belong to the space group P3(1)21 with the unit cell parameters a = b = 119.97 Å, c = 118.10 Å, α = β = 90° and γ = 120°. Structural comparisons show that Alr(SP )shares both an overall fold and key active site residues with other bacterial alanine racemases. The active site cavity is similar to other Gram positive alanine racemases, featuring a restricted but conserved entryway. CONCLUSIONS: We have solved the structure of Alr(SP), an essential step towards the development of an accurate pharmacophore model of the enzyme, and an important contribution towards our on-going alanine racemase structure-based drug design project. We have identified three regions on the enzyme that could be targeted for inhibitor design, the active site, the dimer interface, and the active site entryway. BioMed Central 2011-05-25 /pmc/articles/PMC3146814/ /pubmed/21612658 http://dx.doi.org/10.1186/1471-2180-11-116 Text en Copyright ©2011 Im et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Im, Hookang Sharpe, Miriam L Strych, Ulrich Davlieva, Milya Krause, Kurt L The crystal structure of alanine racemase from Streptococcus pneumoniae, a target for structure-based drug design |
title | The crystal structure of alanine racemase from Streptococcus pneumoniae, a target for structure-based drug design |
title_full | The crystal structure of alanine racemase from Streptococcus pneumoniae, a target for structure-based drug design |
title_fullStr | The crystal structure of alanine racemase from Streptococcus pneumoniae, a target for structure-based drug design |
title_full_unstemmed | The crystal structure of alanine racemase from Streptococcus pneumoniae, a target for structure-based drug design |
title_short | The crystal structure of alanine racemase from Streptococcus pneumoniae, a target for structure-based drug design |
title_sort | crystal structure of alanine racemase from streptococcus pneumoniae, a target for structure-based drug design |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3146814/ https://www.ncbi.nlm.nih.gov/pubmed/21612658 http://dx.doi.org/10.1186/1471-2180-11-116 |
work_keys_str_mv | AT imhookang thecrystalstructureofalanineracemasefromstreptococcuspneumoniaeatargetforstructurebaseddrugdesign AT sharpemiriaml thecrystalstructureofalanineracemasefromstreptococcuspneumoniaeatargetforstructurebaseddrugdesign AT strychulrich thecrystalstructureofalanineracemasefromstreptococcuspneumoniaeatargetforstructurebaseddrugdesign AT davlievamilya thecrystalstructureofalanineracemasefromstreptococcuspneumoniaeatargetforstructurebaseddrugdesign AT krausekurtl thecrystalstructureofalanineracemasefromstreptococcuspneumoniaeatargetforstructurebaseddrugdesign AT imhookang crystalstructureofalanineracemasefromstreptococcuspneumoniaeatargetforstructurebaseddrugdesign AT sharpemiriaml crystalstructureofalanineracemasefromstreptococcuspneumoniaeatargetforstructurebaseddrugdesign AT strychulrich crystalstructureofalanineracemasefromstreptococcuspneumoniaeatargetforstructurebaseddrugdesign AT davlievamilya crystalstructureofalanineracemasefromstreptococcuspneumoniaeatargetforstructurebaseddrugdesign AT krausekurtl crystalstructureofalanineracemasefromstreptococcuspneumoniaeatargetforstructurebaseddrugdesign |